Document:

Exhibit 10.58

 

 

April
20, 2000

 

Dr.
Steven L. Stice

ADS
Complex 

University
of Georgia 

Athens,
GA 30602

 

 

Re:      Advanced Cell Technology, Inc. (“ACT”)

 

Dear
Steve:

 

This
letter is to confirm, in accordance with that certain Letter Agreement dated
July 2, 1998 (as amended by the Extension of Letter Agreement dated September
15, 1998) between you and ACT, and as agreed in our recent discussions
regarding said Letter Agreement, that in consideration of your agreement to
continue your employment with ACT during the summer of 1998 and ACT’s payment
to you of the sum of Three Hundred Thousand Dollars ($300,000.00), plus
interest at the rate of 8.25% from October 15, 1998 to April 14, 2000,
you relinquish, and assign to ACT, all of your rights and/or claims to equity
interests of any form now or previously existing in ACT, CIMA Biotechnology,
Inc. and Cyagra, LLC.

 

Please
acknowledge and confirm your understanding and acceptance of the foregoing by
signing this letter where indicated below and returning it to me. Upon receipt
of the signed letter we will deliver to you our check in the amount of Three
Hundred Thirty-Nine Thousand, Three Hundred and Seventy Six Dollars and
Thirteen Cents ($339,376.13).

 

Thank
you for your cooperation regarding this matter. 

 

Very
truly yours,

 

	
  ADVANCED
  CELL TECHNOLOGY, INC.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Michael
  D. West

  	
   

  	
   

  
	
  Printed
  Name: Michael D. West, Ph.D.

  	
   

  
	
  Its:  President
  and Chief Executive Officer

  	
   

  
	
   

  	
   

  
	
   

  	
  SEEN
  AND AGREED TO:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/
  Steven L. Stice

  	
   

  
	
   

  	
  Steven
  L. SticeExhibit
10.59

 

MASTER LABORATORY
SERVICE AGREEMENT

 

This Master Laboratory
Service Agreement (“Agreement”) made as of the 4th day of January, 2001
between ADVANCED CELL TECHNOLOGY, Inc. One Innovation Drive, Worcester, MA
01605 (hereinafter referred to as Sponsor) and WHITE EAGLE LABORATORIES, INC.,
2003 Lower State Road, Doylestown, PA 18901 (hereinafter referred to as “White
Eagle”) Sponsor and White Eagle hereinafter sometimes referred to as the “parties”).

 

WHEREAS, White Eagle has
certain expertise in the area of collecting oocytes from felines; and provides
contract services related thereto; and

 

WHEREAS, Sponsor desires
to engage White Eagle to provide certain services; and

 

WHEREAS, White Eagle and
Sponsor agree that such services will be provided in accordance with the terms
and conditions of this Agreement;

 

NOW THEREFORE, in
consideration of the premises and the mutual covenants contained herein, the
parties agree as follows:

 

1.             White Eagle shall perform the services (the “Work”) and
deliver materials (the “Deliverables”) as defined and in accordance with
Schedule A attached hereto. If following the execution of this Agreement a
significant change or supplement to the Work or scope of Work is warranted,
such change shall be made by a written notification or change order mutually
agreed upon and signed by the parties prior to the implementation of the
change.

 

In full consideration for all Work to be provided by
White Eagle hereunder, and for the Deliverables, Sponsor shall pay White Eagle
the total sum of Fifteen Thousand Dollars ($15,000) for each month in which
Work resulting in the collection in oocyte recoveries for Sponsor is conducted.
Sponsor shall also pay White Eagle Two Thousand Five Hundred Dollars ($2,500)
for each cat used in the Work for embryo transfer.

 

Sponsor shall pay White Eagle Fifteen Thousand Dollars
for the first month of Work involving oocyte recovery upon acceptance of this
Agreement. White Eagle shall thereafter render to Sponsor an invoice on a
monthly basis for additional Work and embryo transfers performed since the date
of the last invoice. Each invoice shall provide sufficient details so that
verification of the Work and/or the Deliverables provided can be thoroughly and
quickly ascertained by the person reviewing the invoice. Sponsor agrees that
the undisputed portion of each invoice shall be payable upon receipt.

 

 

2.             It is agreed and understood by the parties that all Work
performed hereunder is part of a non-clinical laboratory study which will be
conducted in compliance with and pursuant to all applicable laws, including the
Federal Food and Drug Administration Good Laboratory Practices as set forth in
21 CFR Part 58, et al., when such is incorporated in protocol.

 

3.             White Eagle agrees that during the course of conducting
the Work hereunder White Eagle will permit authorized representatives of the
United States Department of Agriculture or the Food and Drug Administration to
review records, raw data and specimens pertaining to Work performed hereunder
which is in the possession or control of White Eagle. During the performance of
its duties hereunder, White Eagle shall permit authorized representatives of
the United States Department of Agriculture or the Food and Drug Administration
to inspect its facilities utilized in the performance of Work hereunder. White
Eagle agrees to accompany such authorized representatives of the United States
Department of Agriculture or the Food and Drug Administration while such
representatives inspect its facilities and to advise Sponsor of such inspections
to enable Sponsor when practicable, to accompany such authorized
representatives.

 

4.             During the term of this Agreement, White Eagle shall
permit Sponsor or Sponsor Representative to inspect its facilities at mutually
convenient times; to monitor the Work through periodic visits and discussion
with appropriate personnel and to review or copy any documentation relating to
the Work being performed under this Agreement.

 

5.             Except for any Deliverables to be delivered to Sponsor
as provided in Schedule A, all data, including raw data, tissues, slides,
photomicrographs, records and other materials generated during the conduct of
the studies shall be retained by White Eagle for at least 10 years or as otherwise
necessary to meet regulatory and legal requirements. After the expiration of
such requirements, White Eagle will transfer possession of such data to Sponsor.  All such data and materials shall be owned by
Sponsor and treated by White Eagle as confidential information under Paragraph
7 hereof. During, or at the conclusion of the study, Sponsor reserves the right
to request copies of written records, review existing slides, or sample
existing postmortem tissues. Upon conclusion of the study, White Eagle will
transmit to Sponsor all unused materials that were furnished to White Eagle by
Sponsor.

 

6.             It is understood and agreed that White Eagle in
performance of its duties and Work hereunder is acting as an independent
contractor and not as an agent or employee of Sponsor.

 

7.             White Eagle understands that in the performance of the
Work hereunder, it may obtain knowledge of “confidential information”, as
hereinafter defined, relating to the business of Sponsor. As used herein, “confidential
information” means any information including without limitation, any formula,
pattern, device, plan, process or compilation of information or data which (i)
is, or is designed to be, used in the business of Sponsor or results from its
or their research and/or development activities, (ii) is private or confidential
in that it is not generally known or available to the public, and (iii) gives
Sponsor an opportunity to obtain an advantage over competitors who do not know
or use it. White Eagle shall not, without the written consent of an officer of
Sponsor either during the term of this Agreement or for at least a 10 year
period thereafter.

 

 

(a)                                  use
or disclose any such confidential information outside Sponsor;

 

(b)                                 publish
any article with respect thereto;

 

(c)                                  except
in the performance of its services hereunder, remove or aid in the removal from
the premises of Sponsor any such confidential information or any property or
material which relates thereto; or

 

(d)                                 use
confidential information in any manner for White Eagles own benefit or for the
benefit of any third party or parties.

 

White Eagle agrees that
its officers, directors, consultants, and employees shall be bound to the
provisions of confidentiality contained in this paragraph to the same extent as
White Eagle. White Eagle agrees to protect Sponsor’s confidential information
from unauthorized use or disclosure by using the same degree of care as White
Eagle uses to protect its own confidential information of a like nature, but no
less than a reasonable degree of care.

 

8.             It is agreed that this Agreement shall not confer any
right, license, title or interest upon White Eagle in or to any Sponsor patent,
process, plan or improvement or any patent or process owned or controlled by
Sponsor. Sponsor shall own the Deliverables and all inventions and discoveries
resulting from the Work or the Deliverables. White Eagle, upon request and at
Sponsor’s expense, shall execute any documents or instruments required to
reflect its assignments of rights (including any copyrights) in the results of
the Work and will cooperate in the filing and prosecution of any patent
applications or other intellectual property protections.

 

White Eagle agrees that
it shall not publish the results of any research or Work performed under this
Agreement without the prior written permission of Sponsor.

 

9.             The term of this Agreement shall commence as of 1/4, 2001 and shall continue in
effect until White Eagle’s submission of a final report as provided hereunder
or unless terminated sooner as provided herein. Sponsor shall have the
privilege of terminating this Agreement on fourteen (14) days written notice to
White Eagle prior to the date of termination set forth therein.  In the event Sponsor elects to exercise its
right of termination, it shall pay for Work rendered and Sponsor and White Eagle
shall negotiate charges for the remaining Work. Such termination does not
release White Eagle from its obligation of supplying a written report on the
completed segment(s) of the study, if so requested by Sponsor.

 

10.           The provisions and obligations of Paragraphs
5, 7, 8, and 9 shall survive termination of this Agreement.

 

11.           This Agreement is not assignable
except that Sponsor may assign this Agreement to an affiliate or to a successor
in connection with the merger, consolidation, or sale of all or substantially
all of its assets or that portion of its business to which this Agreement
relates. Any attempt to assign this Agreement in contravention of this
paragraph shall be null and void.

 

 

12.           This Agreement shall be deemed to be
a contract under and shall be governed by and construed and enforced in
accordance with the laws of the Commonwealth of Massachusetts, without regard
to principles of conflicts of law thereof.

 

13.           All notices required are permitted to
be given hereunder shall be in writing and shall be delivered personally or by
mail or telegram, and shall be deemed sufficiently given if and when received
by the party to be notified at its address first set forth in this Agreement of
if and when mailed by registered or certified mail, postage prepaid, addressed
to such party at such address. Either party may, by notice to the other, change
its address for receiving such notices and requests.

 

14.           Each party shall be responsible for
the acts or omissions of its own employees and for any claims of personal
injury or property damage resulting there from. Each party will maintain commercially
responsible insurance coverage for its activities under this Agreement.

 

15.           White Eagle shall indemnify and hold
Sponsor harmless from any and all liability, loss, cost, or expense (including
reasonable attorney’s fees and expenses) which Sponsor may suffer or incur
resulting from (a) White Eagle’s, its trustees’, officers’, agents’, or
employees’ failure to comply with any applicable governmental requirements or
to adhere to the terms of this Agreement; or (b) the negligent acts or omission
or willful malfeasance of White Eagle, its trustees, officers, agents, or
employees pertaining to the activities to be carried out pursuant to the terms
of this Agreement; provided, however, that White Eagle shall not hold Sponsor harmless
from claims arising out of the negligence or willful malfeasance of the
Sponsor, its officers, agents, or employees.

 

16.           Sponsor shall indemnify and hold
White Eagle harmless from any and all liability and loss which White Eagle may
suffer or incur as a result of any third party claim of any kind whatsoever
arising out of Sponsor’s use of the results of the Work performed by White
Eagle hereunder, provided, however, that the following is excluded from Sponsor’s
obligation to indemnify and hold harmless: (a) White Eagle’s failure to comply
with any applicable governmental requirements or to adhere to the terms of the
service; or (b) the negligent or willful malfeasance of White Eagle, its trustees,
officers, agents or employees. White Eagle shall notify Sponsor of any third
party claim made against it within ten (10) days of knowledge of same if White
Eagle intends to seek indemnity with respect to such claim under this paragraph.
 Sponsor shall have the right to
undertake, conduct and control, through counsel of its own choosing, the
defense and settlement of any such claim. White Eagle shall have the right to
be represented by counsel of its own choosing, but at its own expense. So long
as Sponsor is contesting any such claim in good faith, White Eagle shall not
pay or settle such claim.

 

 

IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be executed by their respective
authorized representatives as of the day and year first above written.

 

	
  WHITE EAGLE LABORATORIES, INC.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ C. Steven Godin

  	
   

  	
   

  
	
  Printed Name: C. Steven Godin, Ph.D.

  	
   

  
	
  Its:  Director of Toxicology

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  ADVANCED CELL TECHNOLOGY, INC.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Jose Cibelli

  	
   

  	
   

  
	
  Printed Name:

  	
  Jose Cibelli

  	
   

  
	
  Its: 

  	
  VP. RESEARCH

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]